{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006910","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.944206+00:00","generated_at":"2026-06-08T07:35:35.390033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit","bullets":["Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.","Q3 net loss $5.1M ($0.15/sh); 9-month net loss $17M ($0.50/sh), vs $20.2M ($0.60/sh) year ago.","AgenT-797: >30% disease stabilization/biomarker response in heavily pretreated solid tumors; durable gastric cancer response.","Randomized Phase 2 trial of agenT-797 in 2L gastric cancer to launch this year, externally funded, led by MSKCC.","R&D expense down to $3.4M ($6.2M in Q3 2022) as company focuses iNKT platform and cGMP manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006910","json":"https://secwatch.observer/filing/0001171843-23-006910.json","markdown":"https://secwatch.observer/filing/0001171843-23-006910.md","text":"https://secwatch.observer/filing/0001171843-23-006910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/0001171843-23-006910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/f8k_110923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:35:35.390033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54fd09991a86bbce6af72d75db752d7f095fa97c","claim":"MiNK Therapeutics, Inc. reported third quarter 2023 results: net income $17 million, or $0.50 per share, EPS ($0.50).","evidence_excerpt":"Net loss for the nine-months ended September 30, 2023 was $17 million, or $0.50 per share, compared to net loss for the same period in 2022 of $20.2 million or $0.60 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184323006910/0001171843-23-006910-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"$17 million, or $0.50 per share"},{"label":"EPS","value":"($0.50)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}